Listed

Evolent Health, Inc.

EVHNYSECIK 1628908IndustrialsFiscal year ends Dec 31

Latest reported revenue, Q2 FY2026$652.5mRevenue, Q2 FY2026, three months to 2026-06-30$652.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001628908-26-000086.Report this figureThree months to Jun 30, 2026, from the 10-Q filed Aug 6, 2026.

Latest quarter: Q2 FY2026

Three months to Jun 30, 2026, against the same quarter a year earlier.

  • Revenue$652.5mRevenue, Q2 FY2026, three months to 2026-06-30$652.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001628908-26-000086.Report this figure+46.9% on a year earlier
  • Gross marginnot reported (Gross profit not reported)No year-earlier figure to compare
  • Operating margin−1.5%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: −$9.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001628908-26-000086.Revenue: $652.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001628908-26-000086.Report this figure−1.2 pts on a year earlier
  • Net margin−4.3%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: −$28.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001628908-26-000086.Revenue: $652.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001628908-26-000086.Report this figure+0.1 pts on a year earlier
  • Diluted EPS−$0.25Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.25 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001628908-26-000086.Report this figure+43.2% on a year earlier
  • Free cash flownot reported (Capital expenditure not reported)No year-earlier figure to compare

Last eight quarters

Full statements
Revenue$652.5mOperating margin −1.5%
Diluted EPS−$0.25, Q2 FY2026
Evolent Health, Inc., key figures for the last eight quarters
Line itemUnitQ3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Shape over the periods
Revenue$m621Revenue, Q3 FY2024, three months to 2024-09-30$621.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-25, accession 0001628908-26-000015.Report this figure647Revenue, Q4 FY2024, three months to 2024-12-31$646.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-25, accession 0001628908-26-000015.Report this figure484Revenue, Q1 FY2025, three months to 2025-03-31$483.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001628908-26-000033.Report this figure444Revenue, Q2 FY2025, three months to 2025-06-30$444.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001628908-26-000086.Report this figure480Revenue, Q3 FY2025, three months to 2025-09-30$479.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-25, accession 0001628908-26-000015.Report this figure469Revenue, Q4 FY2025, three months to 2025-12-31$468.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-25, accession 0001628908-26-000015.Report this figure496Revenue, Q1 FY2026, three months to 2026-03-31$496.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001628908-26-000033.Report this figure653Revenue, Q2 FY2026, three months to 2026-06-30$652.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001628908-26-000086.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%(2.6%)Operating margin, Q3 FY2024, three months to 2024-09-30. operating income / revenueOperating income: −$16.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-07, accession 0001628908-25-000133.Revenue: $621.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-25, accession 0001628908-26-000015.Report this figure(2.9%)Operating margin, Q4 FY2024, three months to 2024-12-31. operating income / revenueOperating income: −$18.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-25, accession 0001628908-26-000015. Derived: 12-month figure less the 9-month figure.Revenue: $646.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-25, accession 0001628908-26-000015.Report this figure(0.3%)Operating margin, Q1 FY2025, three months to 2025-03-31. operating income / revenueOperating income: −$1.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0001628908-26-000033.Revenue: $483.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001628908-26-000033.Report this figure(0.3%)Operating margin, Q2 FY2025, three months to 2025-06-30. operating income / revenueOperating income: −$1.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001628908-26-000086.Revenue: $444.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001628908-26-000086.Report this figure0.2%Operating margin, Q3 FY2025, three months to 2025-09-30. operating income / revenueOperating income: $886.0k. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-07, accession 0001628908-25-000133.Revenue: $479.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-25, accession 0001628908-26-000015.Report this figure(87.1%)Operating margin, Q4 FY2025, three months to 2025-12-31. operating income / revenueOperating income: −$408.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-25, accession 0001628908-26-000015. Derived: 12-month figure less the 9-month figure.Revenue: $468.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-25, accession 0001628908-26-000015.Report this figure(2.1%)Operating margin, Q1 FY2026, three months to 2026-03-31. operating income / revenueOperating income: −$10.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0001628908-26-000033.Revenue: $496.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001628908-26-000033.Report this figure(1.5%)Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: −$9.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001628908-26-000086.Revenue: $652.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001628908-26-000086.Report this figure
Net margin%(3.7%)Net margin, Q3 FY2024, three months to 2024-09-30. net income / revenueNet income: −$23.1m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-25, accession 0001628908-26-000015.Revenue: $621.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-25, accession 0001628908-26-000015.Report this figure(3.5%)Net margin, Q4 FY2024, three months to 2024-12-31. net income / revenueNet income: −$22.8m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-25, accession 0001628908-26-000015.Revenue: $646.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-25, accession 0001628908-26-000015.Report this figure(13.4%)Net margin, Q1 FY2025, three months to 2025-03-31. net income / revenueNet income: −$64.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-07, accession 0001628908-26-000033.Revenue: $483.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001628908-26-000033.Report this figure(4.5%)Net margin, Q2 FY2025, three months to 2025-06-30. net income / revenueNet income: −$19.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001628908-26-000086.Revenue: $444.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001628908-26-000086.Report this figure(4.4%)Net margin, Q3 FY2025, three months to 2025-09-30. net income / revenueNet income: −$20.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-25, accession 0001628908-26-000015.Revenue: $479.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-25, accession 0001628908-26-000015.Report this figure(91.6%)Net margin, Q4 FY2025, three months to 2025-12-31. net income / revenueNet income: −$429.1m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-25, accession 0001628908-26-000015.Revenue: $468.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-25, accession 0001628908-26-000015.Report this figure(5.4%)Net margin, Q1 FY2026, three months to 2026-03-31. net income / revenueNet income: −$26.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-07, accession 0001628908-26-000033.Revenue: $496.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001628908-26-000033.Report this figure(4.3%)Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: −$28.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001628908-26-000086.Revenue: $652.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001628908-26-000086.Report this figure
Diluted EPS$ per share(0.27)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.27 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-25, accession 0001628908-26-000015.Report this figure(0.27)Diluted EPS, Q4 FY2024, three months to 2024-12-31−$0.27 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-25, accession 0001628908-26-000015.Report this figure(0.63)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.63 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-07, accession 0001628908-26-000033.Report this figure(0.44)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.44 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001628908-26-000086.Report this figure(0.24)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.24 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-25, accession 0001628908-26-000015.Report this figure(3.84)Diluted EPS, Q4 FY2025, three months to 2025-12-31−$3.84 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-25, accession 0001628908-26-000015.Report this figure(0.24)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.24 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-07, accession 0001628908-26-000033.Report this figure(0.25)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.25 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001628908-26-000086.Report this figure
Free cash flow$mnot reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$1.88bnOperating margin −21.9%
Diluted EPS−$5.07, FY2025
Evolent Health, Inc., key figures for the last five fiscal years
Line itemUnitFY20212021-12-31FY20222022-12-31FY20232023-12-31FY20242024-12-31FY20252025-12-31Shape over the periods
Revenue$m908Revenue, FY2021, twelve months to 2021-12-31$908.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-23, accession 0001628908-24-000017.Report this figure1,352Revenue, FY2022, twelve months to 2022-12-31$1.35bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-21, accession 0001628908-25-000020.Report this figure1,964Revenue, FY2023, twelve months to 2023-12-31$1.96bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-25, accession 0001628908-26-000015.Report this figure2,555Revenue, FY2024, twelve months to 2024-12-31$2.55bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-25, accession 0001628908-26-000015.Report this figure1,876Revenue, FY2025, twelve months to 2025-12-31$1.88bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-25, accession 0001628908-26-000015.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%(4.7%)Operating margin, FY2021, twelve months to 2021-12-31. operating income / revenueOperating income: −$42.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2024-02-23, accession 0001628908-24-000017.Revenue: $908.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-23, accession 0001628908-24-000017.Report this figure0.3%Operating margin, FY2022, twelve months to 2022-12-31. operating income / revenueOperating income: $3.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-02-21, accession 0001628908-25-000020.Revenue: $1.35bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-21, accession 0001628908-25-000020.Report this figure(3.6%)Operating margin, FY2023, twelve months to 2023-12-31. operating income / revenueOperating income: −$71.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-25, accession 0001628908-26-000015.Revenue: $1.96bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-25, accession 0001628908-26-000015.Report this figure(1.6%)Operating margin, FY2024, twelve months to 2024-12-31. operating income / revenueOperating income: −$40.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-25, accession 0001628908-26-000015.Revenue: $2.55bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-25, accession 0001628908-26-000015.Report this figure(21.9%)Operating margin, FY2025, twelve months to 2025-12-31. operating income / revenueOperating income: −$410.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-25, accession 0001628908-26-000015.Revenue: $1.88bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-25, accession 0001628908-26-000015.Report this figure
Net margin%(4.1%)Net margin, FY2021, twelve months to 2021-12-31. net income / revenueNet income: −$37.6m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2024-02-23, accession 0001628908-24-000017.Revenue: $908.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-23, accession 0001628908-24-000017.Report this figure(1.4%)Net margin, FY2022, twelve months to 2022-12-31. net income / revenueNet income: −$19.2m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-02-21, accession 0001628908-25-000020.Revenue: $1.35bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-21, accession 0001628908-25-000020.Report this figure(5.8%)Net margin, FY2023, twelve months to 2023-12-31. net income / revenueNet income: −$113.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-25, accession 0001628908-26-000015.Revenue: $1.96bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-25, accession 0001628908-26-000015.Report this figure(2.4%)Net margin, FY2024, twelve months to 2024-12-31. net income / revenueNet income: −$61.6m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-25, accession 0001628908-26-000015.Revenue: $2.55bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-25, accession 0001628908-26-000015.Report this figure(28.5%)Net margin, FY2025, twelve months to 2025-12-31. net income / revenueNet income: −$534.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-25, accession 0001628908-26-000015.Revenue: $1.88bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-25, accession 0001628908-26-000015.Report this figure
Diluted EPS$ per share(0.44)Diluted EPS, FY2021, twelve months to 2021-12-31−$0.44 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-02-23, accession 0001628908-24-000017.Report this figure(0.20)Diluted EPS, FY2022, twelve months to 2022-12-31−$0.20 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-02-21, accession 0001628908-25-000020.Report this figure(1.28)Diluted EPS, FY2023, twelve months to 2023-12-31−$1.28 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-25, accession 0001628908-26-000015.Report this figure(0.81)Diluted EPS, FY2024, twelve months to 2024-12-31−$0.81 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-25, accession 0001628908-26-000015.Report this figure(5.07)Diluted EPS, FY2025, twelve months to 2025-12-31−$5.07 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-25, accession 0001628908-26-000015.Report this figure
Free cash flow$mnot reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.

No open-market purchases or sales by insiders are in coverage for this company.

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding Evolent Health, Inc.
FundQuarter endedReported valueSharesPut or callChange on the quarter before
BlackRock, Inc.2026-06-30$80.3m14,814,851Added+3,925,979
CADIAN CAPITAL MANAGEMENT, LP2026-06-30$58.6m10,814,473Unchanged
MORGAN STANLEY2026-06-30$48.6m8,969,012Reduced−112,067
UBS Group AG2026-06-30$33.8m6,245,283Reduced−1,905,078
Rubicon Founders LLC2026-06-30$31.5m5,816,123Unchanged
Engaged Capital LLC2026-06-30$30.2m5,563,912Unchanged
D. E. Shaw & Co., Inc.2026-06-30$27.7m5,107,561Reduced−326,471
VANGUARD CAPITAL MANAGEMENT LLC2026-06-30$26.0m4,787,994Reduced−79,409
MARSHALL WACE, LLP2026-06-30$18.5m3,413,245Added+2,628,233
Nuveen, LLC2026-06-30$17.0m3,132,085Added+2,866,943

Recent filings

All 836 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

Evolent Health, Inc., recent filings
FiledFormWhat it isAccession number
2026-08-0608:53 ET10-QQuarterly reportPeriod 2026-06-300001628908-26-000086
2026-08-0607:03 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001628908-26-000084
2026-06-0416:05 ET8-K5.07 Shareholder vote results0001628908-26-000037
2026-05-0708:46 ET10-QQuarterly reportPeriod 2026-03-310001628908-26-000033
2026-05-0707:05 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001628908-26-000031
2026-04-2416:13 ETDEF 14AProxy statementPeriod 2026-06-040001193125-26-177267
2026-02-2518:16 ET10-KAnnual reportPeriod 2025-12-310001628908-26-000015
2026-02-2416:12 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001628908-26-000014
2025-12-0808:00 ET8-K8.01 Other events0001628908-25-000145
2025-12-0207:32 ET8-K5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure0001628908-25-000141

Latest annual report

Form 10-K for the fiscal year ended Dec 31, 2025Filed Feb 25, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by [object Promise].Forecast this quarter

About the filer

CIK
1628908
Tickers
EVH
Exchange
NYSE
SIC code
8741 Services-Management Services
Sector
Industrials
Fiscal year ends
Dec 31
Incorporated in
DE
Filer category
Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:44 ET. Listed shows no prices and gives no investment advice.